

1647
PATENT APPLICATION#12C/jrw
01-15-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Egrie et al.

Serial No.: 09/559,001

Group Art Unit No.: 1647

Filed: April 21, 2000

Examiner: DeBerry, R.

For: Methods and Compositions for the Prevention and Treatment of Anemia

Docket No.: A-460A

RECEIVED
JAN 14 2002
TECH CENTER 1600/2900AMENDMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated September 28, 2001, Paper No. 11, please amend this application as follows:

In the Specification

At page 7, replace the third paragraph, line 13, with the following:

Description of the Figures

Figure 1 (SEQ ID NO: 1) shows the amino acid sequence of human erythropoietin.

At page 9, replace the second paragraph, line 11, with the following:

Figure 10 (SEQ ID NO: 25) shows the amino acid sequence of the hinge, CH2 and CH3 regions of human IgGy1.

At page 9, replace the third paragraph, line 14, with the following:

Figure 11 (SEQ ID NO: 26) shows the cDNA and amino acid sequence of Epo N47-Fc fusion polypeptide including the Epo signal sequence. The amino terminal Fc residue is fused to the arg-166 residue of Epo.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Box Amendment, Washington, D.C. 20231, on the date appearing below

October 25, 2001

Date

Signature